Famitinib plus chemo and immunotherapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early or locally advanced triple negative breast cancer (Stage II or III).
- You are generally active (able to do light housework or office work).
- You have not had chemotherapy, radiation, or targeted therapy for breast cancer in the past year.
- You have not taken immunotherapy drugs (like Keytruda) before.
- You do not have active hepatitis B or C, or serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
This trial tests a combination of two drugs, camrelizumab and famitinib, given after surgery to remove cervical cancer. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.